Biomarker Analysis Services for Leishmaniasis
Ace Therapeutics offers specialized biomarker analysis services tailored exclusively for leishmaniasis drug discovery and preclinical development. Our comprehensive biomarker panel is designed to advance understanding of leishmaniasis pathophysiology, supporting therapeutic research from early discovery through preclinical stages. Please note that all services are strictly research-focused and do not include clinical diagnostic testing or support for clinical decision-making.
The foundation of effective therapeutic intervention lies in precise biomarker discovery and identification. At Ace Therapeutics, our biomarker discovery services are integral to the drug development pipeline for leishmaniasis. We employ systematic screening and validation processes, combining in silico analyses, high-throughput screening, and functional assays to identify and characterize molecular targets. Our approach ensures that candidate biomarkers are rigorously evaluated for relevance to disease mechanisms, providing actionable insights for target selection and lead optimization.
Multi Omics: Our multi-omics strategy leverages cutting-edge technologies including genomics, transcriptomics, proteomics, and metabolomics to enable comprehensive study of biological systems in leishmaniasis. This integrated approach allows us to identify DNA, RNA, protein, and metabolite biomarkers associated with disease progression, host-pathogen interactions, and therapeutic response. By interrogating key pathways such as immune response modulation, lipid metabolism, and cellular stress responses, we generate holistic molecular profiles that inform the development of novel therapeutic strategies.
Candidate Validation: Candidate biomarker validation at Ace Therapeutics involves multi-tiered strategies, including cross-platform verification, functional assays, and association studies with leishmaniasis pathophysiology. Preliminary screening processes utilize bioinformatics, literature mining, and experimental data to prioritize candidates with the strongest evidence for disease relevance. Criteria for selection include biological plausibility, reproducibility, specificity to leishmaniasis-associated pathways, and feasibility of assay development.
Diverse Technological Platforms: We offer custom assay development capabilities on a variety of technological platforms, ensuring adaptability to specific research requirements in leishmaniasis. Our platforms include immunoassay systems, liquid chromatography-mass spectrometry (LC-MS/MS), flow cytometry, molecular diagnostics (PCR/qPCR), and advanced histopathology and imaging modalities. Each platform is optimized for sensitivity, specificity, and scalability to support diverse biomarker analysis needs.
Immunoassays: We utilize ELISA, chemiluminescent immunoassays, and multiplex bead-based assays for quantitative and multiplexed detection of proteins and cytokines relevant to leishmaniasis research.
Mass Spectrometry: Our LC-MS/MS platforms enable high-sensitivity, high-specificity quantification of proteins, peptides, lipids, and metabolites implicated in disease pathways.
Flow Cytometry: Advanced flow cytometry is employed for cellular phenotyping, functional assays, and quantification of surface and intracellular markers in immune cell populations.
Molecular Diagnostics: We offer nucleic acid-based analyses, including PCR and quantitative PCR, for detection and quantification of gene expression and genetic variation.
Histopathology And Imaging: Tissue-based biomarker localization and quantification are performed using immunohistochemistry, immunofluorescence, and digital imaging techniques to support morphological and spatial analyses.
Rigorous Method Validation: All analytical methods developed at Ace Therapeutics undergo rigorous validation in accordance with preclinical research guidelines. We assess performance characteristics including sensitivity, specificity, accuracy, precision, linearity, and reproducibility. Comprehensive quality control measures, such as internal standards, reference controls, and inter-assay comparisons, are implemented to ensure data integrity and reliability throughout the research process.
Our quantitative analysis capabilities encompass absolute and relative quantification of biomarker levels across a variety of sample types. We employ validated calibration standards, robust normalization strategies, and statistical analyses to generate high-quality, reproducible data that support hypothesis-driven research in leishmaniasis.
Sample Analysis: Ace Therapeutics handles a broad spectrum of sample types, including blood, serum, plasma, tissue homogenates, cultured cells, and experimental animal samples. Each sample undergoes standardized processing protocols, and all analyses are performed under stringent quality control conditions to minimize variability and ensure reproducibility. Our protocols are tailored to preserve biomarker integrity and maximize analytical sensitivity.
High Throughput Capabilities: We deploy multiplexed analytical platforms and automated workflows to support high-throughput biomarker screening and quantification. These capabilities enable efficient processing of large sample cohorts, reduce turnaround times, and conserve valuable biological material. Multiplexing strategies facilitate simultaneous measurement of multiple biomarkers, enhancing data depth and experimental efficiency.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) | 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is a key enzyme in the mevalonate pathway, which is responsible for the biosynthesis of cholesterol and other isoprenoids. HMGCR catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in cholesterol production. This enzyme is predominantly localized in the endoplasmic reticulum membrane of cells, particularly in the liver, and is subject to complex regulation by feedback mechanisms involving sterols and nonsterol metabolites. HMGCR activity is tightly controlled at the transcriptional, translational, and post-translational levels, reflecting its central role in maintaining cholesterol homeostasis. | HMGCR expression and activity have been utilized as indicators of cholesterol biosynthetic activity in various physiological and pathological contexts. Measurement of HMGCR levels can provide information about cholesterol metabolism status, and changes in HMGCR expression have been observed in metabolic disorders such as hypercholesterolemia and atherosclerosis. HMGCR is also the pharmacological target of statin drugs, and its expression or activity has been studied to monitor statin efficacy and resistance. Additionally, HMGCR has been investigated in cancer research, where altered cholesterol metabolism may be reflected by changes in HMGCR expression. |
| abhydrolase domain containing 12, lysophospholipase (ABHD12) | ABHD12 (abhydrolase domain containing 12) is a serine hydrolase enzyme that functions as a lysophospholipase. It is primarily involved in the hydrolysis of lysophosphatidylserine (LPS) and other lysophospholipids, thereby regulating their levels in the central nervous system and peripheral tissues. ABHD12 plays a critical role in lipid metabolism and the maintenance of lipid homeostasis. Mutations in ABHD12 are associated with the neurodegenerative disorder PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract), highlighting its importance in neural function and integrity. | ABHD12 has been investigated as a biomarker in the context of PHARC, where mutations or altered expression are associated with disease presence. Additionally, changes in ABHD12 activity or expression have been studied in relation to neurodegenerative diseases and inflammatory conditions, reflecting its role in lipid signaling and neuroinflammation. Its measurement may provide information about disease mechanisms or progression in these contexts. |
| aldo-keto reductase family 1 member B (AKR1B1) | Aldo-keto reductase family 1 member B (AKR1B1) encodes an enzyme that belongs to the aldo-keto reductase superfamily. This enzyme catalyzes the reduction of a wide range of aldehydes and ketones to their corresponding alcohols using NADPH as a cofactor. AKR1B1 is best known for its role in the polyol pathway, where it reduces glucose to sorbitol. This activity is particularly relevant in tissues where glucose metabolism is high. In addition to glucose metabolism, AKR1B1 also participates in the detoxification of lipid peroxidation-derived aldehydes and regulates cellular redox homeostasis. Its expression has been observed in various tissues, including the lens, kidney, and nervous system. | AKR1B1 has been investigated as a biomarker in multiple contexts. Its increased expression has been reported in certain cancers, such as breast and colorectal cancer, and is associated with tumor progression and poor prognosis in some studies. Elevated AKR1B1 levels have also been observed in diabetic complications, including diabetic nephropathy and retinopathy, due to its involvement in the polyol pathway. Measurement of AKR1B1 expression or activity has been explored for its potential to assist in disease characterization, risk assessment, and monitoring of disease progression. |
| aldo-keto reductase family 1 member C3 (AKR1C3) | Aldo-keto reductase family 1 member C3 (AKR1C3) is an enzyme that belongs to the aldo-keto reductase superfamily. It catalyzes the NADPH-dependent reduction of a broad range of substrates, including prostaglandins, androgens, estrogens, and xenobiotics. AKR1C3 plays a significant role in steroid hormone metabolism by converting androstenedione to testosterone and estrone to estradiol. It is also involved in the metabolism of prostaglandin D2 to 9α,11β-PGF2 and prostaglandin H2 to prostaglandin F2α, which are important in inflammation and cell proliferation. The enzyme is expressed in various tissues, including liver, prostate, breast, and endometrium, and contributes to the regulation of local steroid concentrations and prostaglandin signaling. | AKR1C3 has been studied as a biomarker in several disease contexts, particularly in oncology. Its expression levels have been investigated in prostate cancer, where increased AKR1C3 expression has been observed in castration-resistant and advanced disease states. Similarly, elevated AKR1C3 expression has been reported in acute myeloid leukemia (AML), breast cancer, and endometrial cancer. In these settings, AKR1C3 expression may be used to characterize disease subtypes, monitor disease progression, or evaluate therapeutic responses. Additionally, AKR1C3 has been explored as a potential marker for predicting resistance to hormone-based therapies. |
| alpha glucosidase (GAA) | Alpha glucosidase (GAA) is a lysosomal enzyme responsible for catalyzing the hydrolysis of alpha-1,4- and alpha-1,6-glucosidic linkages in glycogen, converting it into free glucose. This enzymatic activity is essential for the proper degradation of glycogen within lysosomes, thereby maintaining cellular energy homeostasis and preventing the accumulation of glycogen in tissues. Mutations or deficiencies in GAA activity lead to impaired glycogen breakdown and subsequent lysosomal storage, most notably in the context of Pompe disease (glycogen storage disease type II). | Measurement of GAA enzyme activity or detection of GAA gene mutations is utilized to support the diagnosis of Pompe disease. Reduced GAA activity in blood, dried blood spots, fibroblasts, or muscle tissue can indicate lysosomal glycogen accumulation characteristic of this disorder. Genetic analysis of the GAA gene can further assist in identifying pathogenic variants. These approaches are used in newborn screening programs and in the clinical evaluation of individuals with symptoms suggestive of Pompe disease. |
| cathepsin B (CTSB) | Cathepsin B (CTSB) is a lysosomal cysteine protease belonging to the papain family. It is involved in intracellular protein degradation and turnover, playing a key role in the normal catabolic processes of the cell. CTSB is synthesized as an inactive proenzyme and becomes activated in the acidic environment of the lysosome. In addition to its housekeeping functions, CTSB can participate in the processing of prohormones and the degradation of extracellular matrix components when secreted or mislocalized. Its activity is tightly regulated under physiological conditions, but dysregulation can contribute to pathological processes, including inflammation and tumor progression. | Cathepsin B has been studied as a biomarker in various diseases, particularly in oncology. Elevated levels of CTSB expression or activity have been observed in several types of cancer, including breast, colorectal, and pancreatic cancers, where it has been associated with tumor invasion and metastasis. Measurement of CTSB in tissue samples, serum, or other biological fluids has been explored for potential use in disease diagnosis, prognosis, and monitoring of therapeutic response. In addition, CTSB has been investigated as a biomarker in neurodegenerative and inflammatory diseases. |
| farnesyl-diphosphate farnesyltransferase 1 (FDFT1) | Farnesyl-diphosphate farnesyltransferase 1 (FDFT1), also known as squalene synthase, is an essential enzyme in the cholesterol biosynthesis pathway. It catalyzes the first committed step in the formation of cholesterol by converting two molecules of farnesyl diphosphate (FPP) into squalene. This step occurs downstream of the mevalonate pathway and is critical for the production of sterols and other isoprenoids. FDFT1 is localized to the endoplasmic reticulum membrane and is regulated by cellular cholesterol levels, contributing to the feedback control of cholesterol homeostasis. | Alterations in the expression or activity of FDFT1 have been investigated in the context of several diseases, particularly in oncology and metabolic disorders. Studies have reported differential expression of FDFT1 in various tumor types, including hepatocellular carcinoma and prostate cancer, where its levels may correlate with disease progression or prognosis. Additionally, FDFT1 expression has been explored as an indicator of cholesterol biosynthesis activity in metabolic studies. These applications are based on observed associations between FDFT1 expression and pathological states. |
| fatty acid synthase (FASN) | Fatty acid synthase (FASN) is a multifunctional enzyme complex that catalyzes the de novo synthesis of long-chain saturated fatty acids from acetyl-CoA and malonyl-CoA in the presence of NADPH. FASN is primarily responsible for the synthesis of palmitate (C16:0), which can be further elongated or desaturated to produce other fatty acids. This enzyme plays a central role in lipid biosynthesis, energy storage, and membrane formation. FASN activity is tightly regulated in normal tissues, with high expression in lipogenic tissues such as liver, adipose tissue, and lactating mammary gland. In most adult tissues, FASN expression is low due to the presence of dietary fatty acids, which suppress its synthesis. | FASN has been studied as a biomarker in various types of cancer, including breast, prostate, ovarian, and lung cancers. Elevated FASN expression has been observed in tumor tissues compared to normal tissues, and increased levels have been associated with tumor progression, aggressiveness, and poor prognosis in several malignancies. Immunohistochemical detection of FASN protein or measurement of its mRNA expression has been used to differentiate malignant from benign tissues and to assess disease stage in research settings. FASN expression has also been explored as a potential indicator of metabolic alterations in cancer and other diseases characterized by altered lipid metabolism. |
| heme oxygenase 1 (HMOX1) | Heme oxygenase 1 (HMOX1) is an inducible enzyme that catalyzes the degradation of heme into biliverdin, free iron, and carbon monoxide. This reaction is a critical step in heme catabolism and plays a central role in cellular defense mechanisms against oxidative stress. HMOX1 is upregulated in response to various stimuli, including oxidative stress, hypoxia, heavy metals, and inflammatory cytokines. Its activity contributes to cytoprotection by reducing pro-oxidant heme levels and generating products with antioxidant (biliverdin/bilirubin), anti-inflammatory (carbon monoxide), and iron-sequestering (ferritin induction) properties. HMOX1 is expressed in many tissues, with particularly high levels in the liver, spleen, and other organs involved in erythrocyte turnover. | HMOX1 expression levels have been studied as a biomarker of cellular and tissue response to oxidative stress and inflammation. Increased HMOX1 expression has been observed in conditions such as acute and chronic inflammation, cardiovascular diseases, neurodegenerative disorders, and certain cancers. Its upregulation can reflect cellular adaptation to oxidative injury or inflammatory stimuli. HMOX1 has also been investigated as a marker of tissue injury in organ transplantation and as an indicator of environmental or pharmacological stress in toxicology studies. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF), also known as TNF-alpha, is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as other immune and non-immune cells. TNF plays a central role in inflammation, immune system regulation, cell proliferation, differentiation, apoptosis, and host defense against infections. It exerts its effects by binding to TNF receptors (TNFR1 and TNFR2), initiating signaling cascades that lead to the activation of nuclear factor kappa B (NF-κB), mitogen-activated protein kinases (MAPKs), and caspases. These pathways mediate a variety of cellular responses, including the production of other cytokines, upregulation of adhesion molecules, and promotion of leukocyte recruitment to sites of inflammation. TNF is also involved in the pathogenesis of several autoimmune and inflammatory diseases. | TNF levels in blood, tissue, or other biological fluids are frequently measured as indicators of inflammatory activity. Elevated TNF concentrations have been observed in conditions such as rheumatoid arthritis, inflammatory bowel disease, sepsis, and certain cancers. Quantification of TNF can aid in assessing disease activity, monitoring response to anti-TNF therapies, and, in some contexts, may help in prognosis or risk stratification. Its measurement is commonly performed using immunoassays such as ELISA or multiplex cytokine panels. |
Explore Research Opportunities with Ace Therapeutics. Our biomarker research services provide advanced capabilities for exploratory and preclinical leishmaniasis research, leveraging state-of-the-art technologies and scientific expertise. Please note that all biomarkers discussed are considered research targets only; we do not claim any as validated or mandatory for therapeutic development. Our focus remains on the discovery and characterization of candidate markers during preclinical research stages, maintaining scientific objectivity and supporting collaborative innovation.
We invite you to connect with Ace Therapeutics to discuss collaborative biomarker research for leishmaniasis. Our approach emphasizes scientific exploration and knowledge exchange, supporting preclinical research without claims of biomarker validation or necessity. Let’s advance our understanding together through professional and objective scientific collaboration.
Make Order
Experimental Scheme
Implementation
Conclusion
